NCT03216070 is a Phase 4 clinical trial of Dasatinib 50 MG in Chronic Myelogenous Leukemia, sponsored by Hospital Universitario Dr. Jose E. Gonzalez.

Who is sponsoring NCT03216070?

NCT03216070 is sponsored by Hospital Universitario Dr. Jose E. Gonzalez.

What drugs are being tested in NCT03216070?

Interventions in NCT03216070: Dasatinib 50 MG.

What condition does NCT03216070 study?

NCT03216070 studies Chronic Myelogenous Leukemia.

Is NCT03216070 still recruiting?

NCT03216070 is currently status unknown. Last updated 13 July 2017.

Last reviewed 2017-07-13 · How we verify

NCT03216070

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia

Status unknown Phase 4 Last updated 13 July 2017

What this trial tests

Phase 4 trial testing Dasatinib 50 MG in Chronic Myelogenous Leukemia in 12 participants. Status unknown.

Timeline

1 April 2016

Primary endpoint
1 October 2018

1 October 2018

Quick facts

Lead sponsor	Hospital Universitario Dr. Jose E. Gonzalez
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 April 2016
Primary completion	1 October 2018
Estimated completion	1 October 2018
Sites	1 location across Mexico

Drugs / interventions tested

Dasatinib 50 MG — full drug profile →

Conditions studied

Chronic Myelogenous Leukemia — all drugs for Chronic Myelogenous Leukemia →

Sponsor

Hospital Universitario Dr. Jose E. Gonzalez

Who can join

16 and older, female only, with Chronic Myelogenous Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our goal is to demonstrate that 50mg of dasatinib is as effective as the full dose to induce molecular response as first line therapy in CML.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Is There a Role for Dose Modification of TKI Therapy in CML?
Copland M. · · 2019 · cited 24× · PMID 31197525 · DOI 10.1007/s11899-019-00524-w
Senescent cells: A new Achilles' heel to exploit for cancer medicine?
Zhang B, Lam EW, Sun Y. · · 2019 · cited 20× · PMID 30450821 · DOI 10.1111/acel.12875
Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1.
Villalba M, Redin E, Exposito F, Pajares MJ, et al · · 2019 · cited 14× · PMID 31659178 · DOI 10.1038/s41598-019-51066-3

Verify or expand the search:

Other recruiting trials for Chronic Myelogenous Leukemia

Currently open trials in the same condition.

NCT06680661 — ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis · Phase 2 · recruiting
NCT06088888 — TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia · Phase 1 · recruiting
NCT06131801 — Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution · recruiting
NCT05805605 — Allo HSCT Using RIC and PTCy for Hematological Diseases · Phase 2 · recruiting
NCT04877522 — Asciminib Roll-over Study · Phase 4 · recruiting

Other Hospital Universitario Dr. Jose E. Gonzalez trials

Trials by the same sponsor.

NCT07401992 — Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis · Phase 4 · recruiting
NCT06758375 — Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients · Phase 2 · recruiting
NCT06904599 — Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment · Phase 2 · recruiting
NCT07039877 — Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients · Phase 2 · recruiting
NCT06209190 — Safety and Feasibility of TMLI as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03216070 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Universitario Dr. Jose E. Gonzalez
Last refreshed: 13 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03216070.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing